Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant ...
Investorideas.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (Nasdaq: TVRD) shares surge after Phase 1 results show TTI-109 matched TTI-101's exposure with better tolerability and clear STAT3 target engagement.
GEN

Inflammatory Diseases Kindled When HDAC Proteins Act on Th17 Cells

Scientists from the Icahn School of Medicine at Mount Sinai (MSSM) have published a study that describes the biological mechanism used by a family of proteins called histone deacetylases to activate ...
ascopubs.org

Effect of lactobacillus rhamnosus DY801 on methionine metabolism and Th17 cells in the treatment of acute radiochemotherapy induced bowel injury.

Assessment of chemotherapy-induced nausea and vomiting in adult patients with hematopoietic stem-cell transplant at a tertiary care hospital. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Naturopathic Doctor News and Review

Reduction of Thyroid Antibodies with Tirzepatide in Hashimoto’s Thyroiditis: A Metabolic-Immune Case Report

Explore how low-dose tirzepatide improved insulin resistance and reduced thyroid antibodies in a Hashimoto’s thyroiditis patient. Read the full case report.